Bellicum Pharmaceuticals
A clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.
Launch date
Employees
Market cap
AUD1.2m
Enterprise valuation
(AUD70m) (Public information from Feb 2024)
Share price
$0.0747 BLCM
Houston Texas (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 7.1m | <1m | 6.2m | 1.5m | <1m |
| % growth | - | (93 %) | 1140 % | (76 %) | (99 %) |
| EBITDA | (68.2m) | (53.6m) | (24.3m) | (28.9m) | - |
| % EBITDA margin | (954 %) | (10717 %) | (393 %) | (1929 %) | - |
| Profit | (112m) | (7.7m) | (9.7m) | (25.0m) | - |
| % profit margin | (1575 %) | (1544 %) | (157 %) | (1665 %) | - |
| R&D budget | 64.5m | 39.1m | 23.6m | 22.8m | - |
| R&D % of revenue | 903 % | 7810 % | 380 % | 1518 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$1.5m | Grant | ||
| N/A | $500k | Early VC | |
| N/A | $4.5m | Series A | |
| N/A | $1.2m | Debt | |
| N/A | $5.7m | Early VC | |
$20.0m | Series B | ||
| N/A | $14.7m | Series B | |
$94.4m | Series C | ||
| Total Funding | AUD218m | ||
Related Content
Recent News about Bellicum Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.